

Next Generation Product Released to Health Professionals

- Next generation version of Microba's healthcare product released to health professionals from today
- Product provides 55 new clinical interventions and a new clinical report
- New product will be the most comprehensive and actionable clinical microbiome test available on market

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a precision microbiome company, has released a next generation product for health professionals under a closed beta access program.

The new product will enable health professionals to comprehensively assess gut microbiome biomarkers and identify opportunities to intervene through diet, lifestyle and supplementation. The new clinical report will significantly advance the clinical utility of microbiome testing and support patient management.

The beta access program enables select practitioners to get early access ahead of a wider market release.

Microba's Chief Scientific Officer Associate Professor Lutz Krause said, "The new healthcare product delivers the latest clinical information available from gut microbiome testing. This encompasses information drawn from over 1,000 peer-reviewed publications and supporting data from Microba's large proprietary Databank."

Commenting on the product release, **Microba's Head of Healthcare Operations Ms Hayley Parcell** said, "We have been working closely with health professionals to advance the clinical use of microbiome testing. As a leader in the field, we have worked to deliver the best microbiome test to assist them in supporting their patients' health. We believe this new product will be a foundational shift in the industry and ultimately set a new benchmark for clinical microbiome testing."

Microba has been pioneering the clinical application of microbiome testing since the launch of the Company's first test in 2018. The new product will be the most comprehensive and actionable microbiome test available for health professionals in the market.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.